Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study

Stock Information for Connect Biopharma Holdings Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Connect Biopharma Holdings Limited

Connect Biopharma Announces $20.2 Million Private Placement Financing
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD
Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference
Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026
Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference
Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update
Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.